XTalks

AUGUST 28, 2020

Egorov told Xtalks that, “many studies being carried out right now show that one of the major ways that people get infected with COVID or any other virus or bacteria is not by sharing the bacteria [directly] by sneezing or coughing, but by [touching surfaces], holding hands and then rubbing the nose and eyes.

Containment 111

Containment Bacteria Marketing Production 111

pharmaphorum

APRIL 26, 2022

The microbiome, as a term, can be related to the nasal, oral, skin, gastro-intestinal, and urogenital regions of the human body, each containing varied microbial communities that have an impact on health. If approved by the FDA, the treatment would become the first microbiome-based treatment to receive approval.

Containment 115

Containment Development Production Drugs 115

The Pharma Data

JUNE 18, 2021

Food and Drug Administration (FDA) has approved PREVNAR 20 (Pneumococcal 20-valent Conjugate Vaccine) for the prevention of invasive disease and pneumonia caused by the 20 Streptococcus pneumoniae (pneumococcus) serotypes in the vaccine in adults ages 18 years and older. Following today’s FDA approval, the U.S.

Vaccine 52

Vaccine Vaccination FDA Approval Containment 52

XTalks

MAY 17, 2024

The settlement requires Totality to take several specific corrective actions, which include refraining from making any statements that suggest the spa’s products are genuine, FDA-approved Lilly products, and stopping the use of Eli Lilly branding in promoting any of the products.

Sales 52

Sales FDA Approval Pharmacy Production 52

The Pharma Data

JULY 18, 2021

Food and Drug Administration (FDA) approved VAXNEUVANCE ™ (Pneumococcal 15-valent Conjugate Vaccine) (pronounced VAKS-noo-vans) for active immunization for the prevention of invasive disease caused by Streptococcus pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, 22F, 23F and 33F in adults 18 years of age and older.

Immune Response 52

Immune Response Vaccine Vaccination FDA Approval 52

XTalks

AUGUST 2, 2023

Comirnaty was first approved by the US Food and Drug Administration (FDA) in August 2021 for individuals over the age of 16. It contains the antiviral medications nirmatrelvir and ritonavir. In addition, the FDA approved Pfizer’s pneumococcal 20-valent conjugate vaccine, Prevnar 20, for the first time in June 2021.

Sales 98

Sales Manufacturing FDA Approval Life Science 98

XTalks

FEBRUARY 11, 2025

billion Company/developer: Gilead Sciences Date of first FDA approval: February 7, 2018 FDA-approved indications: HIV-1 Price of Biktarvy: The list price of Biktarvy is $4,216 per month. Biktarvy (Bictegravir/Emtricitabine/Tenofovir Alafenamide) Biktarvy 2023 sales: $11.85 Why it sold so well: Biktarvy generated $11.85

Sales 66

Sales FDA Approval Vaccine Vaccination 66